Orphan designation: Cedazuridine / decitabine Treatment of myelodysplastic syndromes, 16/08/2023 Positive | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 1 February 2024 - 17:38

Orphan designation: Cedazuridine / decitabine Treatment of myelodysplastic syndromes, 16/08/2023 Positive

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2825

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters